Cargando…
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 second...
Autores principales: | Stork, Martin, Sevcikova, Sabina, Minarik, Jiri, Krhovska, Petra, Radocha, Jakub, Pospisilova, Lenka, Brozova, Lucie, Jarkovsky, Jiri, Spicka, Ivan, Straub, Jan, Pavlicek, Petr, Jungova, Alexandra, Jelinek, Tomas, Sandecka, Viera, Maisnar, Vladimir, Hajek, Roman, Pour, Ludek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297924/ https://www.ncbi.nlm.nih.gov/pubmed/34726261 http://dx.doi.org/10.1111/bjh.17925 |
Ejemplares similares
-
P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
por: Vlachová, M., et al.
Publicado: (2022) -
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022) -
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
por: Bezdekova, Renata, et al.
Publicado: (2021) -
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022) -
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)